Compare Dow Inc (DOW) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Nuwellis Inc — how do they compare? Dow Inc trades at $28.35 (market cap $20.06B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: Dow Inc is far larger — about 9118.2× Nuwellis Inc's market cap, and Dow Inc pays a 5.04% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and Nuwellis Inc for 26 Days on average.
| DOW | NUWE | |
|---|---|---|
Market Cap | $20.06B | $2.20M |
Volume | 7,817,231 | 121,544 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $146.65 |
52-Week Low | $20.65 | $0.68 |
Typical Hold Time | 82 Days | 26 Days |
Enterprise Value | $35.75B | -$1.52M |
Dividend Yield | 5.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $27.77, down 1.38% with bearish technical signals. The company shows mixed fundamentals with negative net income margin of -3.13% and ROE of -7.86%, though recent earnings have beaten expectations. Cash flow trends show operational improvement from $1.03B in 2025 to projected $3.9B in 2026. Analyst consensus is mixed with 27.8% buy ratings and a $34.22 price target, representing 23% upside potential.
While DOW faces margin pressures and declining revenue, the stock trades at attractive valuation multiples with P/S of 0.48. The dividend remains intact with $0.35 payment scheduled for September 2026. Key risks include ongoing profitability challenges and chemical sector headwinds, but earnings beats and cash flow improvement provide potential catalysts for patient investors.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
